Enlivex Ltd. (ENLV)
Enlivex develops Allocetra, a therapy for knee osteoarthritis, and holds RAIN tokens in its treasury. It last closed at $1.05 on Nov 20, down 10.26% on the day.
Key Stats
Last 12 monthsNot reported for this period.
From ENLV's SEC filings, latest 20-F for the period ending Dec 31, 2025 (filed Mar 25). Last 12 months adds up the four latest quarters. Per share figures are left out because the US listing can represent a different number of shares.
Earnings
Full earnings history →Analyst Ratings & Price Targets
Analyst Ratings →- Every upgrade, downgrade and initiation as it happens
- Every price target change, raised or cut
- Consensus rating with the average, high and low targets
- Each firm's full rating history on ENLV
Technical AnalysisPrices may be delayed
The stock is 48% below its 20 day and 363% below its 50 day average. It is 11358% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 15), oversold. The nearest support is the 52 week low at $1.00, and the nearest resistance the Pivot at $1.11.
| RSI (14) | 15.44 | Oversold below 30 | Oversold |
| MACD | -1.32 | Above its signal line | Bullish |
| Stochastic | 14.0 | Near the bottom of its range | Oversold |
| ADX (14) | 66.8 | Strong downtrend | |
| Williams %R | -91.1 | Oversold below −80, overbought above −20 | Oversold |
| CCI (20) | -68.6 | Oversold below −100, overbought above 100 | Neutral |
| Rate of change | −17.3% | Change over 10 sessions | Bearish |
| ATR (14) | $0.40 | Typical daily range, 38.4% of price |
| RSI (14) | 17.47 | Oversold below 30 | Oversold |
| MACD | -40.53 | Above its signal line | Bullish |
| Stochastic | 0.1 | Near the bottom of its range | Oversold |
| ADX (14) | 36.9 | Trending down | |
| Williams %R | -99.8 | Oversold below −80, overbought above −20 | Oversold |
| CCI (20) | -72.2 | Oversold below −100, overbought above 100 | Neutral |
| Rate of change | −93.2% | Change over 10 sessions | Bearish |
| ATR (14) | $13.09 | Typical daily range, 1246.3% of price |
What happened before
See how ENLV did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.
Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.
Seasonality
How ENLV has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2008.
Whale Options FlowPrices may be delayed
90DNo whale options trades in ENLV in the last 90 days.
ENLV Institutional Ownership
Full report →- ▼17 buying vs 24 selling
- ▼Shares held by funds -91.1%
- ▼Funds holding -8
- ●Superinvestors: 1 added, 1 cut
- ●Put/call not meaningful
| Q3 2026 | This quarter | Last quarter | Change |
|---|---|---|---|
| Funds holding | 17 | 25 | −32.0% |
| In funds' top 10 | 0 | 0 | – |
| Held by funds | – | – | – |
| New / increased | 17 / 0 | 5 / 9 | +21.4% |
| Reduced / sold out | 0 / 24 | 7 / 13 | +20.0% |
| Put/call ratio | – | – | – |
From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.
AI Auto Pilots
Paper tradingStreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether ENLV is in one of them and how their past ENLV trades turned out.
ENLV News Tone and PricePrices may be delayed
Macro & Market News
All StreetAlpha news →StreetAlpha hasn't covered ENLV in an article yet. Here's the latest on the wider market.
- Announces Positive Interim DSMB Safety Review, Supporting Continued Enrollment in Phase IIb Knee Osteoarthritis Trial
- Enlivex Ltd. Notice and Proxy Statement for the Extraordinary General Meeting of Shareholders to Be Held on December 4, 2026
- Announces Pricing of $7.5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
- Enlivex Announces Favorable 12-Month Topline Data from
- Enlivex Announces Randomization of 135 Patients
- Enlivex Announces Receipt of Delisting Notice
- Announces 1-for-16 Reverse Share Split to be Effective October 27, 2026
About Enlivex
Enlivex is a drug development company based in Tel Aviv. It is developing Allocetra, a therapy designed to rebalance the immune system, and is testing it as a possible treatment for knee osteoarthritis, a joint condition linked to aging. The company also holds a treasury of RAIN, the governance token of a decentralized prediction markets platform built on the Arbitrum network.
- Headquarters
- Tel Aviv

